The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 27, 2016
Filed:
Dec. 31, 2014
Development Center for Biotechnology, New Taipei, TW;
Dcb-usa Llc, Wilmington, New Castle, DE (US);
National Health Research Institutes, Miaoli County, TW;
Shih-Chong Tsai, New Taipei, TW;
Ta-Tung Yuan, New Taipei, TW;
Shih-Chi Tseng, New Taipei, TW;
Jiann-Shiun Lai, New Taipei, TW;
Chia-Cheng Wu, New Taipei, TW;
Chao-Yang Huang, New Taipei, TW;
Ya-Wei Tsai, New Taipei, TW;
Ying-Yung Lok, New Taipei, TW;
Chung-Hsiun Wu, New Taipei, TW;
Neng-Yao Shih, Miaoli County, TW;
Ko-Jiunn Liu, Miaoli County, TW;
Li-Tzong Chen, Miaoli County, TW;
Development Center for Biotechnology, New Taipei, TW;
DCB-USA LLC, Wilmington, New Castle, DE (US);
National Health Research Institutes, Miaoli County, TW;
Abstract
A humanized antibody, or a binding fragment thereof, wherein the humanized antibody binds human ENO1 (GenBank: AAH50642.1), wherein the antibody comprises a light chain variable region (VL) domain comprising a CDR1 having the amino acid sequence LCDR1 (RASENIYSYLT; SEQ ID NO: 6) and a CDR2 having the amino acid sequence LCDR2 (NAKTLPE; SEQ ID NO: 7) and a CDR3 having the amino acid sequence LCDR3 (QHHYGTPYT; SEQ ID NO: 8) and an antibody heavy chain variable region (VH) domain comprising a CDR1 having the amino acid sequence HCDR1 (GYTFTSCVMN; SEQ ID NO: 3), a CDR2 having the amino acid sequence HCDR2 (YINPYNDGTKYNEKFKG; SEQ ID NO: 4) and a CDR3 having the amino acid sequence HCDR3 (EGFYYGNFDN; SEQ ID NO: 5), wherein framework regions in the light chain variable region (VL) domain and the heavy chain variable region (VH) domain comprise amino acid sequences from a human immunoglobulin.